Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C)

Christina A. Rostad, MD,⁎ Ann Chahroudi, MD, PhD,⁎⁎⁎⁎ Grace Mantus, BS,⁎⁎ Stacey A. Lapp, MS, MPH,⁎⁎⁎ Matthew Linam, MD,⁎⁎ Matthew G. Zimmerman, BS,⁎⁎⁎⁎ Pei-Yong Shi, PhD,⁎ Vineet D. Menachery, PhD,⁎ Matthew E. Øster, MD, MPH,⁎ Srilatha Edupuganti, MD,⁎ Evan J. Anderson, MD,⁎⁎⁎ Mehul S. Suthar, PhD,⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎⁎PLEMENTARY TABLE 1: Demographic and Clinical Characteristics of Children With MIS-C, Those With Coronavirus Disease 2019, Those With Kawasaki Disease, and Hospitalized Controls

<table>
<thead>
<tr>
<th>MIS-C (n = 10)</th>
<th>COVID-19 (n = 10)</th>
<th>Kawasaki Disease (n = 4)</th>
<th>Hospitalized Controls (n = 17)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>7.4 (4.6–12.5)</td>
<td>5.0 (2.5–10.5)</td>
<td>6.1 (3.5–12.1)</td>
</tr>
<tr>
<td>Sex (male/total)</td>
<td>5/10 (50%)</td>
<td>6/10 (60%)</td>
<td>2/4 (50%)</td>
</tr>
<tr>
<td>Race (white/total)</td>
<td>8/10 (80%)</td>
<td>9/10 (90%)</td>
<td>4/4 (100%)</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Chest pain (50%)</td>
<td>60%</td>
<td>100%</td>
</tr>
<tr>
<td>Fever</td>
<td>80%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>Rash</td>
<td>0%</td>
<td>0%</td>
<td>50%</td>
</tr>
<tr>
<td>Arthritis</td>
<td>0%</td>
<td>0%</td>
<td>25%</td>
</tr>
<tr>
<td>Skin changes</td>
<td>0%</td>
<td>0%</td>
<td>50%</td>
</tr>
<tr>
<td>Cardiac involvement</td>
<td>40%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>Pulmonary symptoms</td>
<td>0%</td>
<td>0%</td>
<td>100%</td>
</tr>
<tr>
<td>Gastrointestinal symptoms</td>
<td>0%</td>
<td>0%</td>
<td>100%</td>
</tr>
</tbody>
</table>

HOW WE DO IT

We aimed to measure severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serological responses in children hospitalized with multisystem inflammatory syndrome in children (MIS-C) compared with those with coronavirus disease 2019 (COVID-19), those with Kawasaki disease (KD), and hospitalized pediatric controls.

RESULTS: All children with MIS-C had high titers of SARS-CoV-2 RBD IgG antibodies, which correlated with full-length spike IgG antibodies (R² = 0.956; P < .001), nucleocapsid protein antibodies (R² = 0.846; P < .001), and neutralizing antibodies (R² = 0.667; P < .001). Children with MIS-C had significantly higher SARS-CoV-2 RBD IgG antibody titers (geometric mean titer 6800; 95% confidence interval 3495–13 231) than children with COVID-19 (geometric mean titer 626; 95% confidence interval 251–1563; P < .001), children with KD (geometric mean titer 124; 95% confidence interval 91–170; P < .001), and hospitalized controls (geometric mean titer 85; P < .001). All children with MIS-C also had detectable RBD immunoglobulin M antibodies, indicating recent SARS-CoV-2 infection. RBD IgG titers correlated with the erythrocyte sedimentation rate (R² = 0.512; P < .046) and with hospital (R² = 0.548; P = .014) and ICU lengths of stay (R² = 0.590; P = .010).

CONCLUSIONS: Quantitative SARS-CoV-2 serology may have a role in establishing the diagnosis of MIS-C, distinguishing it from similar clinical entities, and stratifying risk for adverse outcomes.

WHAT’S KNOWN ON THIS SUBJECT: Although the clinical features of a multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 have been recently described, the serological features of MIS-C are unknown.

WHAT THIS STUDY ADDS: In this case series, all hospitalized children with MIS-C had significantly higher severe acute respiratory syndrome coronavirus 2 binding and neutralizing antibodies than children with coronavirus disease 2019 or Kawasaki disease. Severe acute respiratory syndrome coronavirus 2 antibodies correlated with metrics of systemic inflammation and clinical outcomes, suggesting diagnostic and prognostic value.

The majority of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in children are either mild or asymptomatic, with a small subset requiring hospitalization.1 However, reports of a severe inflammatory syndrome in children after the onset of SARS-CoV-2 transmission have recently emerged in areas with a high prevalence of coronavirus disease 2019 (COVID-19).2-8 Many of these children have had clinical features similar to Kawasaki disease (KD),6,7,9,10 and they have had high rates of hemodynamic instability, myocardial involvement,11 and respiratory failure requiring intensive care-level support. On May 14, 2020, the US Centers for Disease Control and Prevention (CDC) released a health advisory and a preliminary case definition for this clinical entity, which they termed multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19.12 Although the clinical features of MIS-C have been described, the quantitative SARS-CoV-2 serological responses in these children in comparison with children hospitalized with COVID-19 are unknown. In this study, we measured antibodies to several immunogens of SARS-CoV-2, the spike protein receptor-binding domain (RBD), the full-length spike protein, and the nucleocapsid protein, and neutralizing antibodies in children hospitalized with MIS-C compared with those with COVID-19, those with KD, and other hospitalized controls.

METHODS

Setting and Patient Population

Children and young adults (0–21 years of age) hospitalized at Children’s Healthcare of Atlanta (CHOA) from March 17, 2020, to May 26, 2020, were eligible for enrollment for prospective and/or residual blood collection. Residual samples consisted of plasma or sera leftover from clinical laboratory tests. With institutional review board approval, at the time of enrollment, prospective samples were collected when parental consent was possible and residual samples were obtained if consent was not possible. Demographic, clinical, laboratory, and outcome data were obtained through abstraction of the electronic medical record and were recorded on a standardized case report form. Data abstracted included age, sex, self-reported race and ethnicity, BMI (which was determined at the time of hospitalization for all children ≥2 years of age), underlying medical conditions, and presenting signs and symptoms. Gastrointestinal symptoms were defined as any reported abdominal pain, nausea, vomiting, or diarrhea at the time of presentation. Respiratory symptoms were defined as any upper respiratory (nasal congestion or rhinorrhea) or lower respiratory sign or symptom (cough, chest pain, dyspnea, difficulty breathing, hypoxia, or hypercarbia) at the time of presentation.

Laboratory values abstracted included the maximum white blood cell count; minimum absolute lymphocyte count; minimum platelet count; minimum serum sodium, maximum alanine aminotransferase, and maximum C-reactive protein (CRP) level; maximum erythrocyte sedimentation rate (ESR), and maximum D-dimer level obtained before administration of intravenous immunoglobulin (IVIg) (if given) or during the hospitalization (if IVIg was not given). These laboratory tests were selected because they have been associated with MIS-C in previous reports.6,7 The majority of children in our cohort did not have laboratory data available for serum troponin, brain-natriuretic peptide, procalcitonin, prothrombin or partial thromboplastin time, interleukin 6, or soluble interleukin 2R, so these were not included in the analysis.

Treatment data abstracted included the administration of IVIg, systemic corticosteroids, convalescent plasma, remdesivir, immunomodulators (eg, anakinra, tocilizumab), and hydroxychloroquine. Patient outcome data abstracted included the duration of hospitalization, admission to and duration of ICU care, requirement for inotropes or vasopressors (any) for shock, the development of respiratory failure (defined as requiring high-flow nasal cannula or greater respiratory support), and death.

Definition of Cohorts

MIS-C

Children who met the CDC case definition12 were classified as having MIS-C if they had SARS-CoV-2 nucleocapsid protein antibodies detected by a clinician-ordered qualitative, commercially available assay (Abbott Laboratories, Chicago, IL) or if they had nasopharyngeal detection of SARS-CoV-2 by real-time polymerase chain reaction (RT-PCR). The molecular test performed at CHOA for inpatients during this time period was the DiaSorin Molecular Simplexa COVID-19 Direct RT-PCR assay, which has an analytical sensitivity or limit of detection (LOD) of 500 viral copies per mL when specimens are collected by using
COVID-19
Symptomatic hospitalized children who tested positive for SARS-CoV-2 by nasopharyngeal RT-PCR and did not meet the CDC case definition for MIS-C were classified as having COVID-19.

KD
Children were classified as having complete \((n = 3)\) or incomplete \((n = 2)\) KD by using American Heart Association criteria.\(^{15}\)

Hospitalized Controls
Additional contemporaneous hospitalized children who were evaluated for possible COVID-19 or MIS-C but tested negative for SARS-CoV-2 by clinician-ordered nasopharyngeal RT-PCR and measurement of qualitative nucleocapsid protein antibodies were included as controls.

SARS-CoV-2 Enzyme-Linked Immunosorbent Assays
We previously described the cloning, expression, and purification of a recombinant form of the spike RBD from SARS-CoV-2.\(^{16}\)

We measured anti-RBD antibodies using enzyme-linked immunosorbent assays (ELISAs) in duplicate, as described.\(^{16}\)

We similarly performed ELISAs for the full-length spike (HexaPro,\(^{17}\) courtesy of Jason McLellan) and nucleocapsid proteins (Sino Biological, Wayne, PA). Secondary antibodies used for development included anti-human-IgG-HRP, anti-human-IgM-HRP, and anti-human-HRP (Jackson ImmunoResearch Laboratories, Inc, West Grove, PA).

Plates were developed by using o-Phenylenediamine substrate, and absorbance was read at 490 nm. Absorbance curves were generated by using nonlinear regression analysis, and end point titers were interpolated from curves by using a baseline value calculated from the pooled sera of 8 healthy controls. The assay LOD was 100, and undetectable titers were assigned a value of 85.

Focus-Reduction Neutralization Assays
An infectious clone of the full-length mNeonGreen SARS-CoV-2 (2019-nCoV/USA_WA1/2020) was generated, as previously described.\(^{18}\)

Serially diluted patient serum or plasma and virus were combined and incubated at 37°C for 1 hour. The antibody-virus mixture was aliquoted onto a monolayer of VeroE6 cells and incubated at 37°C for 1 hour. The inoculum was removed, and medium supplemented with 1% methylcellulose was added. Plates were incubated at 37°C for 24 hours and were then fixed with 2% paraformaldehyde. Green fluorescent foci were visualized by using an enzyme-linked immune absorbent spot reader (Cellular Technology Limited, Shaker Heights, OH).

Green fluorescent protein–based focus-reduction neutralization test (FRNT\(_{50}\)) curves were generated by using nonlinear regression analysis. Titers were expressed as the serum dilution at which fluorescent foci were reduced by 50% (FRNT\(_{50}\)). The assay LOD was defined by the starting dilution of serum samples, which was either 1:20 or 1:40. For graphing purposes, the LOD was represented as 40, and all undetectable titers were assigned a value of 20.

Statistical Methods
Descriptive statistics and statistical comparisons were made by using GraphPad Prism version 8.0. Frequencies were compared by using \(\chi^2\) tests, and continuous variables were compared by using one-way analysis of variance (ANOVA) with Tukey’s post hoc analysis. Linear regression was performed on log-transformed antibody titers, and the coefficient of determination \((R^2)\) values were determined. P values \(\leq 0.05\) were considered statistically significant.

RESULTS
Baseline Characteristics
During the study period, a total of 66 children were hospitalized at CHOA with either MIS-C \((n = 12)\) or COVID-19 \((n = 54)\). We enrolled 10 children with MIS-C, 10 children with COVID-19, 5 children with KD (Table 1), and 4 hospitalized controls (Supplemental Table 2) who had sera available for analysis. Two of the children with MIS-C had concurrently positive SARS-CoV-2 nasopharyngeal RT-PCR results, and their clinical presentation of MIS-C appeared to coincide with symptomatic COVID-19. Children with MIS-C had a median age of 8.5 years (interquartile range [IQR] 6.5–12 years) (Table 1, Supplemental Fig 4A), and the majority were of male sex, Black race, and non-Hispanic ethnicity and were previously healthy with a normal BMI (Supplemental Fig 4B). In contrast, 8 (80%) children with COVID-19 had an underlying medical comorbidity, and 3 (30%) were immunocompromised. Two of these children were receiving induction chemotherapy for new diagnoses of acute myelogenous leukemia, and 1 child was receiving consolidation chemotherapy for rhabdomyosarcoma.

The distinguishing laboratory features of MIS-C included elevated D-dimer levels.
absolute lymphopenia, and thrombocytopenia.

Gastrointestinal symptoms were predominant at the time of presentation, although half of the children with MIS-C also had respiratory symptoms. Six (60%) children developed myocardial dysfunction, and 1 child (10%) developed a borderline coronary ectasia. Children with MIS-C were significantly more likely to require admission to the ICU (P = .005) and to have shock requiring inotropes or vasopressors (P < .001) compared with children with COVID-19 or KD. All children with MIS-C received IVIg, and half received corticosteroids (Table 1, Supplemental Table 3). All children with MIS-C and KD were ultimately discharged from the hospital.

However, 2 children with COVID-19 and acute myelogenous leukemia died of presumed bacterial sepsis after prolonged hospitalizations (48 and 74 days). Another child with COVID-19 remained hospitalized for management of underlying comorbidities at the time of publication. Of the 9 children with MIS-C who had ≥3 weeks of outpatient follow-up data available, all had resolution or near resolution of their clinical signs and symptoms. None had developed late-onset cardiovascular complications after hospital discharge.

### Serological Responses

All children with MIS-C and the majority of children with COVID-19 (90%) had detectable immunoglobulin G (IgG) antibodies to SARS-CoV-2 spike protein RBD (Fig 1A). The child with COVID-19 who had undetectable antibodies had only mild respiratory symptoms. In contrast, children with KD had minimally reactive antibodies, and all hospitalized controls had undetectable antibody responses. When statistically compared, children

<table>
<thead>
<tr>
<th>TABLE 1 Characteristics of Children With MIS-C, COVID-19, and KD</th>
<th>MIS-C (n = 10)</th>
<th>COVID-19 (n = 10)</th>
<th>KD (n = 5)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographic characteristics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, y, median (IQR)</td>
<td>8.5 (6.5–12)</td>
<td>16 (2.7–18.3)</td>
<td>3 (1–6.5)</td>
<td>0.017</td>
</tr>
<tr>
<td>Sex, female, n (%)</td>
<td>4 (40)</td>
<td>5 (50)</td>
<td>2 (40)</td>
<td>0.885</td>
</tr>
<tr>
<td>Race, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>6 (60)</td>
<td>4 (40)</td>
<td>2 (40)</td>
<td>0.537</td>
</tr>
<tr>
<td>White</td>
<td>3 (30)</td>
<td>6 (60)</td>
<td>3 (60)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>1 (10)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Ethnicity, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hispanic</td>
<td>2 (20)</td>
<td>5 (50)</td>
<td>1 (20)</td>
<td>0.289</td>
</tr>
<tr>
<td>Clinical characteristics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI, median (IQR)</td>
<td>18.8 (17.7–24.4)</td>
<td>26.8 (18.5–31)</td>
<td>17 (14.1–18.7)</td>
<td>0.08</td>
</tr>
<tr>
<td>Underlying medical condition (any), n (%)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>3 (30)</td>
<td>8 (80)</td>
<td>0 (0)</td>
<td>0.007</td>
</tr>
<tr>
<td>Immune compromised</td>
<td>0 (0)</td>
<td>3 (30)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Respiratory symptoms</td>
<td>3 (30)</td>
<td>2 (20)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>0 (0)</td>
<td>3 (30)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Respiratory symptoms at presentation, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal symptoms at presentation, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory values&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White blood cell count, cells × 10&lt;sup&gt;9&lt;/sup&gt;/µL, median (IQR)</td>
<td>7.9 (6.1–14.0)</td>
<td>19.8 (13.5–24.1)</td>
<td>16.6 (15.2–17.9)</td>
<td>0.117</td>
</tr>
<tr>
<td>Absolute lymphocyte count, cells per µL, median (IQR)</td>
<td>623 (437–768)</td>
<td>1330 (579–1889)</td>
<td>2632 (942–3324)</td>
<td>0.021</td>
</tr>
<tr>
<td>Platelet count, cells × 10&lt;sup&gt;9&lt;/sup&gt;/µL, median (IQR)</td>
<td>115 (105–151)</td>
<td>249 (30–282)</td>
<td>343 (326–431)</td>
<td>0.01</td>
</tr>
<tr>
<td>Sodium, mmol/L, median (IQR)</td>
<td>133 (129–138)</td>
<td>136 (135–157)</td>
<td>136 (134–138)</td>
<td>0.126</td>
</tr>
<tr>
<td>Alanine aminotransferase, U/L, median (IQR)</td>
<td>97 (82.5–156)</td>
<td>61 (37–124)</td>
<td>79 (18–82)</td>
<td>0.579</td>
</tr>
<tr>
<td>CRP, mg/dL, median (IQR)</td>
<td>48 (11.5–17.7)</td>
<td>8.1 (4.9–11.8)</td>
<td>19.9 (17.7–20.2)</td>
<td>0.124</td>
</tr>
<tr>
<td>ESR, mm/h, median (IQR)</td>
<td>67 (42.3–71.5)</td>
<td>32 (25.5–70)</td>
<td>79 (53–114)</td>
<td>0.453</td>
</tr>
<tr>
<td>D-dimer, ng/ml, median (IQR)</td>
<td>2183 (1735–3732)</td>
<td>1301 (843–1735)</td>
<td>2792</td>
<td>0.034</td>
</tr>
<tr>
<td>Treatments and outcomes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IVIg, n (%)</td>
<td>10 (100)</td>
<td>5 (50)</td>
<td>4 (80)</td>
<td>0.002</td>
</tr>
<tr>
<td>Corticosteroids, n (%)</td>
<td>5 (50)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0.003</td>
</tr>
<tr>
<td>Duration of hospitalization, d, median (IQR)</td>
<td>9 (7.3–11.5)</td>
<td>17 (4–48)</td>
<td>4 (2–5)</td>
<td>0.073</td>
</tr>
<tr>
<td>ICU admission, n (%)</td>
<td>10 (100)</td>
<td>5 (50)</td>
<td>1 (20)</td>
<td>0.005</td>
</tr>
<tr>
<td>Duration of ICU, d, median (IQR)</td>
<td>7 (5.5–8.8)</td>
<td>3 (0–15)</td>
<td>0 (0)</td>
<td>0.28</td>
</tr>
<tr>
<td>Shock (inotropes or vasopressors), n (%)</td>
<td>7 (70%)</td>
<td>5 (50%)</td>
<td>1 (20%)</td>
<td>0.186</td>
</tr>
</tbody>
</table>
| Statistical comparisons were made by using 1-way ANOVA for continuous variables and χ² tests for categorical variables. P values ≤.05 were considered statistically significant. HFNC, high-flow nasal cannula.
|<sup>a</sup> Subjects may have >1 underlying medical condition.
|<sup>b</sup> Laboratory values represent the maximum white blood cell count, minimum absolute lymphocyte count, minimum platelet count, minimum serum sodium level, maximum alanine aminotransferase level, maximum CRP level, maximum ESR, and maximum D-dimer level obtained before administration of IVIg (if given) or during hospitalization (if IVIg not given).
|<sup>c</sup> Only 9 children with COVID-19 and 1 child with KD had D-dimer tests performed. The P value for D-dimer represents a 2-tailed Student’s t test for comparing COVID-19 and MIS-C.
with MIS-C had significantly higher SARS-CoV-2 RBD IgG titers than children with COVID-19, children with KD, and other hospitalized controls (P < .001 for each comparison).

Although the timing of sample collection after the onset of illness was not standardized (Supplemental Fig 5), the days from symptom onset did not differ significantly among children with MIS-C and COVID-19 (P = .816).

We observed that all children with MIS-C and most children with COVID-19 (80%) also had detectable immunoglobulin M (IgM) antibodies to SARS-CoV-2 RBD (Fig 1B). Although children with MIS-C had significantly higher IgM antibody titers than hospitalized control patients, there were not statistical differences between the other groups. Interestingly, 1 child with incomplete KD had a high RBD IgM titer and a negative IgG titer result. Although this child had tested negative for SARS-CoV-2 by nasopharyngeal RT-PCR and qualitative nucleocapsid antibody assay (Abbott Laboratories), her parent did report that she had a respiratory illness 2 weeks preceding her presentation. The child did not meet the case definition of MIS-C because she did not have multiorgan involvement. Nevertheless, her positive IgM titer result suggests that acute SARS-CoV-2 infection may have been an infectious trigger of KD in the absence of clinical findings of MIS-C.

Live-virus neutralization assays were performed by using an mNeonGreen fluorescently labeled SARS-CoV-2 virus (Fig 1C). Whereas all children with MIS-C had detectable neutralization titers to SARS-CoV-2, only 30% of children with COVID-19 had neutralizing antibodies. Children with MIS-C had significantly higher neutralizing antibody titers than children with COVID-19 (P = .006), children with KD (P = .001), and hospitalized controls (P = .002). RBD IgG binding titers strongly correlated with live-virus neutralization titers, as determined by linear regression of the log-transformed titers (R² = 0.674; P < .001) (Fig 1D). These data are consistent with previous studies in which it was found that the RBD IgG was highly discriminatory for neutralizing antibodies in patients with COVID-19, with a sensitivity and specificity of 97.5% and 98%, respectively.

All children with MIS-C and most children with COVID-19 also had detectable antibodies to the SARS-CoV-2 full-length spike and nucleocapsid proteins (Fig 2 A and B). Children with MIS-C had significantly higher full-length spike and nucleocapsid antibody titers than children with COVID-19, children with KD, and hospitalized controls (P < .001 for all comparisons). Both spike and nucleocapsid antibody titers correlated highly with RBD IgG binding titers (R² = 0.956 [P < .001] and R² = 0.846 [P < .001], respectively) (Fig 2 C and D), which implied that the immune responses observed were broadly reactive to SARS-CoV-2 and not specific to a particular antigen. Interestingly, all children with KD had low-level seropositivity to the nucleocapsid protein. This finding may have been attributable to the receipt of IV IgM.
because the nucleocapsid protein shares greater amino acid identity with the circulating endemic human coronavirus strains, resulting in a greater degree of antibody cross-reactivity compared with the spike protein.\textsuperscript{19}

We next performed linear regression analyses to identify correlations between RBD IgG antibody titers and MIS-C clinical and laboratory features. We found that RBD IgG antibody titers correlated positively with the peak ESR obtained before IVIg administration ($n = 8$; $R^2 = 0.512$; $P = .046$) (Fig 1E) but not with peak CRP values ($R^2 = 0.026$; $P = .655$; data not shown). RBD IgG antibody titers also correlated with total hospital length of stay (LOS) ($n = 10$; $R^2 = 0.548$; $P = .014$; data not shown) and ICU LOS ($n = 10$; $R^2 = 0.590$; $P = .010$) (Fig 1F), which were collinear outcome variables. Because all children with MIS-C in our cohort required ICU admission and inotropes or vasopressors for shock, and no children with MIS-C died, the correlation between antibody titers and these patient outcomes could not be ascertained (Fig 3).

**DISCUSSION**

We demonstrated that all children with MIS-C in our cohort had high titers of SARS-CoV-2 RBD IgG antibodies, which correlated with live-virus neutralization. Children with MIS-C also had significantly higher RBD antibody titers than children with COVID-19, children with KD, or hospitalized controls. These results suggest that quantitative SARS-CoV-2 RBD IgG serology may be helpful in establishing the diagnosis of MIS-C and distinguishing it from other syndromes with similar clinical appearances, such as KD. Quantitative serology may also have prognostic value because of SARS-CoV-2 full-length spike and nucleocapsid protein antibodies compared with other cohorts, indicating a broad and robust immune response to SARS-CoV-2. Nevertheless,

**FIGURE 2**

SARS-CoV-2 spike and nucleocapsid protein antibodies. A and B, ELISAs to SARS-CoV-2 full-length spike IgG end point titers (A) and nucleocapsid protein total antibody end point titers (B). C and D, Correlation between log-transformed RBD IgG titers and spike IgG end point titers (C) or nucleocapsid protein end point titers (D) by linear regression. \textsuperscript{***} $P \leq .001$; \textsuperscript{****} $P \leq .0001$.

**FIGURE 3**

Serological correlations in children with MIS-C. A and B, Correlation between RBD IgG end point titers and ESR (A) (millimeters per hour; $n = 8$) and ICU LOS (B) ($n = 10$) in children with MIS-C.
Recently, Godfred-Cato et al. suggested that MIS-C can coincide with acute COVID-19 symptoms at the time of their nasopharyngeal RT-PCR results, indicating that their disease manifestations coincided with and may have been primarily attributable to COVID-19. Children in class 3 (34.7%) had clinical features more closely resembling KD, including younger age, higher frequencies of rash and mucocutaneous involvement, and milder clinical disease course. On the basis of these descriptions, it is likely that 8 (80%) children in our cohort would have been categorized as having class 1 MIS-C, whereas 2 (20%) children would have been categorized as having class 2 MIS-C. This implies that the serological findings in our study may be most useful in distinguishing children with class 1 MIS-C and identifying children with class 2 MIS-C at risk for severe disease. Differentiating these clinical and laboratory phenotypes is necessary for risk stratification because of the differences in clinical management and patient outcomes.

Serological studies in adults have demonstrated that SARS-CoV-2 antibody titers correlate with COVID-19 disease severity. Thus, it seems paradoxical that children in our study without preceding viral symptoms consistent with acute SARS-CoV-2 infection would develop such robust immune responses as demonstrated by high binding and neutralizing antibody titers. Recent data have suggested that children with mild to moderate COVID-19 symptoms can harbor significantly higher nasopharyngeal SARS-CoV-2 viral loads than adults with similar symptoms, as represented by low RT-PCR cycle threshold values. This raises the possibility that some children with high viral loads may develop robust immune responses, even in the absence of clinical symptoms.

The magnitude of antibody responses also correlate with the timing from SARS-CoV-2 exposure and symptom onset. Although the incubation period for COVID-19 has a median time of 4 to 5 days from exposure to symptom onset, the window period between SARS-CoV-2 exposure and the development MIS-C has not been well established. In the minority of children who recall preceding viral symptoms, the number of days to MIS-C onset has ranged from 6 to 79. This wide range likely impacts SARS-CoV-2 antibody titers, which are known to increase by day 7 and plateau at day 14 after onset of COVID-19 symptoms. Further longitudinal studies are needed to determine if convalescent antibody titers in children recovering from COVID-19 rise to similar levels as those in children with MIS-C. These data would help distinguish whether the magnitude of antibody titers observed in children with MIS-C represented an exaggerated immune response to SARS-CoV-2, a delayed complication of COVID-19, or a combination of both.

Our study has several limitations, including a small sample size. Mild or moderate clinical phenotypes of MIS-C may have been underrepresented because of a lack of recognition early during the pandemic. This underscores the need for collaboration among pediatric centers to corroborate clinical and laboratory findings associated with varying clinical phenotypes of MIS-C in larger patient cohorts. Second, detection of SARS-CoV-2 binding and neutralizing antibodies in children with MIS-C demonstrates association but not necessarily causation. Also, because the seroprevalence of SARS-CoV-2 antibodies increases, the clinical significance of these antibodies may eventually become
obscured. Several patients with MIS-C had specimens drawn after administration of IVIg, which conceivably could have affected SARS-CoV-2 antibody titers. However, 4 of 5 patients with KD also received IVIg before specimen collection, with negligible effects on RBD titers. Although RBD IgG antibody titers correlated well with the ESR, they did not correlate with the acute-phase reactant CRP. This may have been, in part, attributable to the timing of sample collection and the response kinetics of ESR to systemic inflammation; however, the ESR can be affected by multiple factors, and these observations warrant further investigation.

CONCLUSIONS

We found that all children with MIS-C in our cohort had high titers of SARS-CoV-2 RBD IgG antibodies, which correlated with viral neutralization. RBD IgG antibodies also correlated with metrics of systemic inflammation and clinical outcomes. Thus, measuring quantitative SARS-CoV-2 RBD antibody titers may have a role in establishing the diagnosis of MIS-C, distinguishing it from other similar clinical entities, and stratifying risk for adverse outcomes.

ACKNOWLEDGMENTS

We thank our colleagues in clinical care, the clinical and research laboratories, and the clinical research nurses and coordinators, without whom this study would not have been possible. We thank Dr Jason McLellan from the Department of Molecular Biosciences, The University of Texas at Austin, for kindly providing the HexaPro pre-fusion stabilized full-length spike protein. We thank our colleagues in radiology, Drs Bradley S. Rostad and Sarah S. Milla, who collaboratively interpreted radiographic images to contribute to early drafts of this article. We thank all the study participants and their families, and we thank our families for their steadfast support.

REFERENCES


ABBREVIATIONS

ANOVA: analysis of variance
CDC: US Centers for Disease Control and Prevention
CHOA: Children’s Healthcare of Atlanta
COVID-19: coronavirus disease 2019
CRP: C-reactive protein
ELISA: enzyme-linked immunosorbent assay
ESR: erythrocyte sedimentation rate
RDFT50: focus-reduction neutralization test
IgG: immunoglobulin G
IgM: immunoglobulin M
IQR: interquartile range
IVIg: Intravenous immunoglobulin
KD: Kawasaki disease
LOS: length of stay
MIS-C: multisystem inflammatory syndrome in children
RBD: receptor-binding domain
RT-PCR: real-time polymerase chain reaction
SARS-CoV-2: severe acute respiratory syndrome coronavirus 2

DOI: https://doi.org/10.1542/peds.2020-018242
Accepted for publication Aug 27, 2020
Address correspondence to Preeti Jaggi, MD, Department of Pediatrics, School of Medicine, Emory University, 2015 Uppergate Dr NE, Atlanta, GA 30322.
E-mail: preeti.jaggi@emory.edu
PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).
Copyright © 2020 by the American Academy of Pediatrics
FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.
FUNDING: Supported by the Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta and Emory University, the Georgia Research Alliance, a Synergy Award from Emory University School of Medicine, and a Fast Grant from Emergent Ventures at the Mercatus Center at George Mason University. The Center for Childhood Infections and Vaccines, the Georgia Research Alliance, George Mason University, and Emory University had no role in the design or conduct of this study.
POTENTIAL CONFLICT OF INTEREST: Dr Anderson has received personal fees from AbbVie and Pfizer for consulting. Dr Rostad receives royalties unrelated to this article to Emory University from Meissa Vaccines, Inc. Drs Anderson and Rostad’s institution receives funds to conduct clinical research unrelated to this article from MedImmune, Regeneron, PaxVax, Pfizer, GlaxoSmithKline, Merck, Novavax, Sanofi-Pasteur, and Micron. Drs Menachery and Shi coinvented the reverse genetics system used to generate the live severe acute respiratory syndrome coronavirus 2 virus described in this article (a patent has been applied for this technology, and it has been licensed for commercial use); the other authors have indicated they have no potential conflicts of interest to disclose.


Downloaded from www.aappublications.org/news by guest on June 13, 2021
Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C)


*Pediatrics* 2020;146;
DOI: 10.1542/peds.2020-018242 originally published online September 2, 2020;

| Updated Information & Services | including high resolution figures, can be found at: http://pediatrics.aappublications.org/content/146/6/e2020018242 |
| References | This article cites 26 articles, 3 of which you can access for free at: http://pediatrics.aappublications.org/content/146/6/e2020018242#BI BL |
| Permissions & Licensing | Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.aappublications.org/site/misc/Permissions.xhtml |
| Reprints | Information about ordering reprints can be found online: http://www.aappublications.org/site/misc/reprints.xhtml |
Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C)


*Pediatrics* 2020;146;
DOI: 10.1542/peds.2020-018242 originally published online September 2, 2020;

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://pediatrics.aappublications.org/content/146/6/e2020018242

Data Supplement at:
http://pediatrics.aappublications.org/content/suppl/2020/11/11/peds.2020-018242.DCSupplemental